References
- Carruthers J. D. A., Carruthers J. A. Treatment of glabellar frown lines with C. Botulinum‐A exotoxin. J Dermatol Surg Oncol 1992; 18: 17–21
- Lowe N. J., Yamauchi P. S., Lask G. P., Patnaik R., Moore D. Botulinum toxins types A and B for brow furrows: preliminary experiences with type B toxin dosing. J Cosmet Laser Ther 2002; 4: 15–8
- Matarasso S. L. Comparison of botulinum types A and B: a bilateral and double‐blind randomized evaluation in the treatment of canthal rhytides. Dermatol Surg 2003; 29: 7–13
- Aoki K. R. A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice. Toxicon 2001; 39: 1815–20
- Aoki K. R. Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety. Toxicon 2002; 40: 923–8
- Foster K. A., Bigalke H., Aoki K. R. Botulinum neurotoxin—from laboratory to bedside. Neurotoxicity Res 2006; 9: 133–40
- Trindade de Almeida A. R., Marques E., de Almeida J., Cunha T., Borasco R. Pilot study comparing the diffusion of two formulations of botulinum toxin type A in patients with forehead hyperhidrosis. Dermatol Surg 2007; 33 special issue: S37–43
- Bhatia K. P., Münchau A., Thompson P. D., Houser M., Chauhan V. S., Hutchinson M., et al. Generalised muscular weakness after botulinum toxin injections for dystonia: a report of three cases. J Neurol Neurosurg Psychiatry 1999; 67: 90–3
- Kessler K. R., Skutta M., Benecke R. Long‐term treatment of cervical dystonia with botulinum toxin type A: efficacy, safety, and antibody frequency. German Dystonia Study Group. J Neurol 1999; 246: 265–74
- Rosales R. L., Bigalke H., Dressler D. Pharmacology of botulinum toxin: differences between type A preparations. Eur J Neurol 2006; 13 suppl 1: 2–10
- Inoue K., Fujinaga Y., Watanabe T., Ohyama T., Takeshi K., Moriishi K., et al. Molecular composition of Clostridium botulinum type A progenitor toxins. Infect Immun 1996; 64: 1589–94
- Schantz E. J., Johnson E. A. Preparation and characterization of botulinum toxin type A for human treatment. Therapy with Botulinum Toxin, J Jankovic, M Hallet. Marcel Dekker, Inc., New York 1994; 41–9
- Hambleton P., Capel B., Bailey N., Heron N., Crooks A., Melling J., . Production, purification and toxoiding of Clostridium botulinum type A toxin. Biomedical Aspects of Botulism, G. E. Jr Lewis, P. S Angel, et al. Academic Press, Inc., New York 1981
- Hirtzer P., Chung J., Dias B., et al. Complex integrity of botulinum toxin type B (NeuroBlocTM): implications for the incidence of secondary non‐responders. Eur J Neurol 2001; 8 suppl 4: 25
- Sampaio C., Costa J., Ferreira J. J. Clinical comparability of marketed formulations of botulinum toxin. Mov Disord 2004; 19(suppl 8)S129–36
- Lew H., Yun Y. S., Lee S. Y., Kim S. J. Effect of botulinum toxin A on facial wrinkle lines in Koreans. Ophthalmologica 2002; 216: 50–4
- Lowe P., Patnaik R., Lowe N. Comparison of two formulations of botulinum toxin type A for the treatment of glabellar lines: a double‐blind, randomized study. J Am Acad Dermatol 2006; 55: 975–80
- Hsu T. S. J., Dover J. D., Arndt K. A. Effect of volume and concentration on the diffusion of botulinum exotoxin A. Arch Dermatol 2004; 140: 1351–4
- Carruthers A., Carruthers J., Cohen J. Dilution volume of botulinum toxin type A for the treatment of glabellar rhytides: does it matter?. Dermatol Surg 2007; 33 special issue: S97–104
- Carruthers J., Fagien S., Matarasso S. L., and the Botox Consensus Group. Consensus recommendations on the use of botulinum toxin type A in facial aesthetics. Plast Reconstr Surg 2004; 114(6 suppl)1S–22S
- BOTOX COSMETIC [prescribing information]. Allergan, Inc., Irvine, (CA) 2005
- Flynn T. C., Clark R. E II. Botulinum toxin type B (MYOBLOC) versus botulinum toxin type A (BOTOX) frontalis study: rate of onset and radius of diffusion. Dermatol Surg 2003; 29: 519–22
- Nüssgens Z., Roggenkämper P. Comparison of two botulinum‐toxin preparations in the treatment of essential blepharospasm. Graefes Arch Clin Exp Ophthalmol 1997; 235: 197–9
- Ascher B., Zakine B., Kestemont P., Baspeyras M., Bougara A., Santini J. A multicenter, randomized, double‐blind, placebo‐controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. J Am Acad Dermatol 2004; 51: 223–33
- Yamauchi P. S., Lowe N. J. Botulinum toxin types A and B: comparison of efficacy, duration, and dose‐ranging studies for the treatment of facial rhytides and hyperhidrosis. Clin Dermatol 2004; 22: 34–9